as regards SNV OTC I think there is a fatal flaw in your research. You are looking backwards at what WAS- instead you should be looking FORWARDS at what might be.
The issue now is will UDHC succeed in rolling out the product offering commercially? That will determine valuation- not what went on 5 years ago.